Diabetic autonomic neuropathy
- PMID: 387501
- DOI: 10.1007/BF01235856
Diabetic autonomic neuropathy
Abstract
This review attempts to outline the present understanding of diabetic autonomic neuropathy. The clinical features have been increasinly recognised but knowledge of the localization and morphology of the lesions and their pathogenesis remains fragmentary. A metabolic causation as postulated in somatic nerves accords best with clinical observations. Most bodily systems, particularly the cardiovascular, gastrointestinal and urogenital, are involved with added disturbances of thermoregulatory function and pupillary reflexes. Possible effects on neuroendocrine and peptidergic secretion and respiratory control await definition. Current interest centres around the development of a new generation of tests of autonomic nerve function that are simple, non-invasive, reproducible and allow precision in diagnosis and accurate quantitation. Most are based on cardiovascular reflexes and abnormality in them is assumed to reflect autonomic damage elsewhere. Probably no single test suffices and a battery of tests reflecting both parasympathetic and sympathetic function is preferable. Little is known of the natural history. The prevalence may be greater than previously suspected and although symptoms are mild in the majority, a few develop florid features. The relation of control and duration of diabetes to the onset and progression of autonomic neuropathy is not clearly established. Once tests of autonomic function become abnormal they usually remain abnormal. Symptomatic autonomic neuropathy carries a greatly increased mortality rate possibly due to indirect mechanisms such as renal failure and direct mechanisms such as cardio-resiratory arrest. Improved treatment of some of the more disabling symptoms has been possible in recent years.
Similar articles
-
Diabetic autonomic neuropathy.Diabetes Care. 2003 May;26(5):1553-79. doi: 10.2337/diacare.26.5.1553. Diabetes Care. 2003. PMID: 12716821 Review.
-
Autonomic neuropathy: its diagnosis and prognosis.Clin Endocrinol Metab. 1986 Nov;15(4):855-88. doi: 10.1016/s0300-595x(86)80078-0. Clin Endocrinol Metab. 1986. PMID: 3536203 Review.
-
Assessment of cardiovascular effects in diabetic autonomic neuropathy and prognostic implications.Ann Intern Med. 1980 Feb;92(2 Pt 2):308-11. doi: 10.7326/0003-4819-92-2-308. Ann Intern Med. 1980. PMID: 7356219
-
Clinical features of diabetic autonomic neuropathy.Horm Metab Res Suppl. 1980;9:50-60. Horm Metab Res Suppl. 1980. PMID: 6929778 No abstract available.
-
Assessment of diabetic autonomic neuropathy using heart rate monitoring.Horm Metab Res Suppl. 1980;9:69-72. Horm Metab Res Suppl. 1980. PMID: 6929780
Cited by
-
Heart rate variability in diabetic patients during orthostatic load--a spectral analytic approach.Klin Wochenschr. 1990 Jan 4;68(1):26-32. doi: 10.1007/BF01648886. Klin Wochenschr. 1990. PMID: 2155343
-
Limited benefit of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: a 24-week controlled trial.Diabetologia. 1985 Jun;28(6):323-9. doi: 10.1007/BF00283137. Diabetologia. 1985. PMID: 3930330 Clinical Trial.
-
Diabetes mellitus and male sexual function: a controlled study.Diabetologia. 1993 Aug;36(8):745-51. doi: 10.1007/BF00401146. Diabetologia. 1993. PMID: 8405742
-
Recommendations from the Canadian Hypertension Society Consensus Conference on Hypertension and Diabetes.CMAJ. 1988 Dec 1;139(11):1059-62. CMAJ. 1988. PMID: 3056600 Free PMC article. Review. No abstract available.
-
Diabetes-induced changes in cardiac beta-adrenoceptor responsiveness: effects of aldose reductase inhibition with ponalrestat.Br J Pharmacol. 1991 Feb;102(2):478-82. doi: 10.1111/j.1476-5381.1991.tb12197.x. Br J Pharmacol. 1991. PMID: 1849772 Free PMC article.